Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months' Administration of Ofatumumab in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Conditions
Interventions
Ofatumumab 3mg
Ofatumumab 30mg
+2 more
Locations
61
United States
GSK Investigational Site
Cullman, Alabama, United States
GSK Investigational Site
Fullerton, California, United States
GSK Investigational Site
Fairfield, Connecticut, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Sunrise, Florida, United States
GSK Investigational Site
Tampa, Florida, United States
Start Date
November 1, 2011
Primary Completion Date
August 23, 2013
Completion Date
June 10, 2015
Last Updated
June 6, 2018
NCT07325292
NCT05748015
NCT06433765
NCT07466823
NCT04876339
NCT05344469
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions